A new drug for amyotrophic lateral sclerosis, or ALS, has cleared a major hurdle on its path toward being produced and ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including ...

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

MRI is a diagnostic test that doctors use to diagnose and track the progress of amyotrophic lateral sclerosis (ALS). ALS is a progressive disease that damages nerve cells in the brain and spinal cord.